Bristol Myers holds on to blockbuster Sotyktu hopes, plays down Otelza threat FiercePharma Bristol Myers Quarterly Profit Tops Estimates Barron's Bristol Myers Q4 revenue falls as Revlimid continues to take hit from generics; outlook Seeking Alpha Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call…
#bristolmyers #otelza #fiercepharma #bristolmyersq4 #bristolmyerssquibb #bmy
Continue reading...